Sitero buys Axiom Real-Time Metrics to expand tech offering

Sitero has acquired e-clinical solutions provider Axiom Real-Time Metrics to expand its digital drug study offering.

The deal will add Axiom’s proprietary platform, data, and operations expertise to Sitero’s offering. Financial terms of the deal were not disclosed.

Sankesh Abbhi, Sitero CEO, cited Axiom’s “technology-forward” approach and a desire to scale-up his firm’s business as motivation for the deal.

“We are creating a more powerful, end-to-end clinical services platform — enabled by advanced technology — that ensures continuity for existing clients while expanding our ability to support trials globally with greater flexibility, scale, and operational excellence.”

Sitero added that the acquisition will advance the integration of AI-driven capabilities into its proprietary Mentor eClinical suite, which it claims is used by more than 100 customers worldwide.

Adding AI and IT to its offering has been a focus for Sitero in recent years. In 2023, for example, the company acquired technology from Clario, adding data capture, randomization, and clinical trial management systems to its business.

And, in February last year, the firm partnered with Arisglobal in a deal focused on “advancing the industry’s adoption of AI-based research and development solutions.” The deal was expanded in September.

Fragmentation

The Axiom acquisition, like the earlier partnerships, is in keeping with recent comments Sitero made about the fragmented nature of the trial technology space.

In a recent blog post, the firm wrote, “Clinical trials are more complex than ever, yet the technology supporting them is often fragmented, disconnected, and inefficient.

“The industry must embrace a unified interconnected clinical trial data ecosystem —one where all study teams, sites, and compliance are seamlessly connected. Achieving this doesn’t mean just integrating systems. It requires true interoperability, where data flows freely between platforms without the need for manual reconciliation.”

The firm added, “The era of disconnected trial systems is coming to an end. Sponsors and CROs must move beyond patchwork integrations and embrace a truly interoperable ecosystem that connects EDC, ePRO, CTMS, RTSM, eConsent, payments, and regulatory tools in a single, seamless workflow.”

DepositPhotos/Westlight